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Small cell lung cancer (SCLC) accounts for only 15% of lung cancers overall,1 but thismalignancy represents the fifth leading cause of cancer mortality in the United States
when considered independently from non-SCLC.2 Because most patients with SCLC
present with advanced nodal disease, with or without systemic involvement, SCLC
represents less than 5% of cases in large surgical series.3 From a historical perspective,
when Mountain4 reviewed the experience of the M.D. Anderson Hospital and Tumor
Institute in the surgical management of 368 patients with pathologically proven SCLC,
they reported 30 years ago that only one patient survived longer than 5 years compared
with 15 to 25% of non-SCLC patients. The discrepancy can be explained by the biologic
behavior of SCLC, which results in dissemination to regional lymph nodes and/or distant
metastatic sites in more than 90% of patients at initial presentation, thereby precluding
surgery. Even patients with apparently “limited-stage” or “operable” tumors probably
have micrometastatic deposits at distant sites, which have the potential to proliferate if
only local therapeutic modalities, such as surgery or radiotherapy, are used. This also
explains the dismal results of the landmark randomized trial of the British Medical
Research Council5 that compared surgical resection with “radical radiotherapy” (30
Gy). Median survivals were only 199 and 300 days in the radiotherapy and surgical arms,
respectively, with only one and three patients alive at 5 years.
The introduction of chemotherapy to the treatment of SCLC led to significant
improvements in survival between the 1970s and 1990s,6 but recently, survival seems to
have reached a plateau for both localized and advanced SCLC. For localized SCLC,
chemotherapy and thoracic radiation represent a global standard of care, and there is
general agreement that surgery has very little role to play in this malignancy.7
In the monumental staging initiative undertaken by the International Association for
the Study of Lung Cancer (IASLC), there were 12,620 cases of SCLC8 in the database
(8088 with complete tumor, node, and metastasis [TNM] staging information). Five-year
survival rates for clinically staged patients with stages IA and IB tumors were 38% and
21%, respectively. Interestingly, 5-year survival rates for stages IIA and IIB were similar
at 38% and 18%, respectively. It has long been recognized that clinical staging does not
correlate with pathologic staging. The IASLC staging project also had complete patho-
logic TNM staging information for 349 cases of SCLC who had undergone surgical
resection,9 making this the largest SCLC surgical series reported to date. Surgically treated
SCLC represented only 1.3% of all fully staged resected cases in the database and only
2.8% of all SCLC cases. Concordance between clinical and pathologic TNM staging was
only 58%. Five-year survival rates for pathologically staged patients with stages IA and
IB tumors were 53% and 44%, respectively, and 43% and 35%, respectively, for stages
IIA and IIB.
In this issue of the Journal, Yu et al.10 have presented the results of their analysis of
247 patients from the National Cancer Institute Surveillance Epidemiology and End
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Results (SEER) database who underwent surgical resection
for SCLC between 1988 and 2004. Of 205 patients with stage
I SCLC who required only lobectomy, the 5-year survival
rate was 50.3%, virtually identical to that reported by Val-
lieres et al.9 from the IASLC analyses. They also seem to be
better than the IASLC results for patients with clinical stage
I SCLC treated without resection.8 The IASLC also applied
their new stage groupings that have been accepted by for the
Union International Contre le Cancer for their seventh edition
of their staging manual to the SEER database (Figure 1). The
5-year SEER survival results for stage I using the new IASLC
groupings remain similar to those reported by Yu et al., even
though their analysis focused mainly on patients who re-
quired only lobectomy.
The conclusion of Yu et al. is that “surgery without
radiotherapy appears to offer reasonable survival outcomes in
patients with stage I SCLC.” Furthermore, they also refer to
consensus documents and guidelines that recommend consid-
eration of curative intent surgery for patients who have small
lesions without clinical evidence of lymph node involvement.
It must be emphasized that these consensus statements and
guidelines represent opinions at best and that these opinions
are based on low level evidence stemming mainly from
reports of retrospective analyses of highly selected cohorts of
patients who underwent surgery, usually at single institutions.
In 40 years, there have been only two (!!) randomized
trials5,11 comparing surgical resection with other forms of
treatment for localized SCLC, and neither of these studies
supported a surgical approach. Of note, although, both trials
antedated the era of modern staging technology, and so they
likely included a very high proportion of patients with “oc-
cult” extrathoracic disease, which might not be occult using
today’s techniques.
The Lung Cancer Study Group initiated the only ran-
domized trial of adjuvant surgical resection after induction
chemotherapy in 1983.11 Most patients with limited stage
tumors, even those with clinically evident mediastinal lymph-
adenopathy were eligible, and induction consisted of a sel-
dom used anthracycline-based regimen without thoracic ra-
diation. Only 144 of the 340 patients who entered the trial
(42%) were randomized (68 surgery and 76 radiotherapy). Of
the 68 patients randomized to surgery, six did not undergo
thoracotomy, and conversely, eight patients had off-study
surgery. The results were disappointing with no difference in
survival between the groups.
Why was survival not improved by surgery, and how
should Lung Cancer Study Group 831 be interpreted? Of
note, 10% of the patients did not receive their randomly
assigned therapy. In such a small study, this 10% serious
protocol violation may have masked a small but significant
survival advantage in one of the arms. Other factors poten-
tially having an even greater impact on the outcome include
(1) the low response rate of only 65% to induction therapy,
(2) the 17% “open and close” surgical rate, (3) the 23%
incomplete resection rate, and perhaps of greater importance,
(4) the high proportion of patients with bulky N2 and N3
nodal involvement.
This leads us back to the conclusion of Yu et al. that
“surgery without radiotherapy appears to offer reasonable
survival outcomes in patients with stage I SCLC.” This may
be true but is surgery the best treatment or a necessary
treatment in this era of platinum-based chemotherapy and the
ability to administer concurrent thoracic radiotherapy in high
doses safely and with acceptable levels of acute and late
toxicity? An Eastern Cooperative Group (ECOG) study that
compared once daily to twice daily thoracic radiotherapy in
patients with limited stage SCLC12 reported a 25% 5-year
survival rate for patients in the twice daily radiotherapy arm.
These results seem to be considerably better than those of
clinically staged patients in the IASLC database.8 Although it
can be argued that the patients in the ECOG study were
highly selected because they were required to meet the strict
eligibility criteria of the trial, the counter argument is that the
majority of the patients in the study likely had clinically
evident N2/N3 involvement. These patients in the IASLC
database, most of whom would not have received concurrent
twice daily radiotherapy, had survival rates of only 13% and
9%. Furthermore, in the ECOG study, the 45-Gy radiation
dose used would be considered modest by today’s standard.
This then leads to the question of what is the expected
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FIGURE 1. Survival of patients who have un-
dergone resection of small cell lung cancer ac-
cording to tumor, node, and metastasis (TNM)
stage using the International Association for the
Study of Lung Cancer (IASLC) stage groupings
proposed for the Union International Contre le
Cancer, 7th edition, applied to the Surveillance
Epidemiology and End Results (SEER) database,
1998–2002. Adapted with permission from
J Thorac Oncol. 2009;4:1049–1059.9
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survival of patients with clinically staged I and II SCLC
treated with cisplatin-based chemotherapy administered with
concurrent radiotherapy at doses of 60 Gy? To date, this
question remains unanswerable. Careful analysis of the pro-
spective trials assessing dose and fractionation of radiother-
apy currently planned or ongoing in North America and
Europe may shed some light on the issue, but only if adequate
clinical TNM staging data are collected prospectively using
the newest (7th Union International Contre le Cancer edition)
staging system (Table 1).
Despite the above arguments, it remains possible that
patients with early-stage SCLC (T1–2 N0 and perhaps even
stage II) or “very limited” to use a phrase coined by the
University of Toronto Thoracic Oncology Group13 may ben-
efit from a combined modality approach that includes sur-
gery. However, very few patients fall into this subgroup
(likely less than 10%), and so it would only be possible to
mount a prospective randomized trial to prove or disprove
that surgery is appropriate in this setting through international
multidisciplinary collaboration. It is time to stop reporting on
single-institution studies and database analyses of surgery for
SCLC. Thoracic oncologists must decide to “fish or cut bait,”
and if they decide to “fish,” the international community must
come together to plan a prospective trial. Such an interna-
tional study would have to allow a certain degree of flexibility
in the selection of chemotherapy and radiation protocols.
Furthermore, in view of the small numbers of eligible pa-
tients, such a study would take years to accrue; however, it
should be allowed to run as long as necessary to answer this
lingering but important question. There is probably only one
more chance to mount this potentially “landmark trial.” Let’s
go fishing!
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TABLE 1. Five-Year Overall Survival Rates by Pathological
TNM Stage for Patients with Completely Resected Small Cell
Lung Cancer in the IASLC Database
TNM
Stages
Version 6 Version 7
N
5-Yr Survival
Rate (%) N
5-Yr Survival
Rate (%)
IA 68 53 55 56
IB 91 44 45 57
IIA 37 43 56 38
IIB 34 35 25 40
IIIA 76 8 68 12
IIIB 33 21 12 0
IASLC, International Association for the Study of Lung Cancer; TNM, tumor, node
metastasis.
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